These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 26732172)

  • 21. Discovery of Akt kinase inhibitors through structure-based virtual screening and their evaluation as potential anticancer agents.
    Chuang CH; Cheng TC; Leu YL; Chuang KH; Tzou SC; Chen CS
    Int J Mol Sci; 2015 Feb; 16(2):3202-12. PubMed ID: 25648320
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rapamycin, a mTOR inhibitor, induced growth inhibition in retinoblastoma Y79 cell via down-regulation of Bmi-1.
    Wang YD; Su YJ; Li JY; Yao XC; Liang GJ
    Int J Clin Exp Pathol; 2015; 8(5):5182-8. PubMed ID: 26191215
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The discovery and optimisation of pyrido[2,3-d]pyrimidine-2,4-diamines as potent and selective inhibitors of mTOR kinase.
    Malagu K; Duggan H; Menear K; Hummersone M; Gomez S; Bailey C; Edwards P; Drzewiecki J; Leroux F; Quesada MJ; Hermann G; Maine S; Molyneaux CA; Le Gall A; Pullen J; Hickson I; Smith L; Maguire S; Martin N; Smith G; Pass M
    Bioorg Med Chem Lett; 2009 Oct; 19(20):5950-3. PubMed ID: 19762236
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design, synthesis, and biological evaluation of imidazo[1,2-b]pyridazine derivatives as mTOR inhibitors.
    Mao B; Gao S; Weng Y; Zhang L; Zhang L
    Eur J Med Chem; 2017 Mar; 129():135-150. PubMed ID: 28235701
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis of Rapamycin Derivatives Containing the Triazole Moiety Used as Potential mTOR-Targeted Anticancer Agents.
    Xie L; Huang J; Chen X; Yu H; Li K; Yang D; Chen X; Ying J; Pan F; Lv Y; Cheng Y
    Arch Pharm (Weinheim); 2016 Jun; 349(6):428-41. PubMed ID: 27150260
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of benzenesulfonamide derivatives as potent PI3K/mTOR dual inhibitors with in vivo efficacies against hepatocellular carcinoma.
    Chen Y; Zhang L; Yang C; Han J; Wang C; Zheng C; Zhou Y; Lv J; Song Y; Zhu J
    Bioorg Med Chem; 2016 Mar; 24(5):957-66. PubMed ID: 26819001
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design, synthesis and docking studies of novel thienopyrimidine derivatives bearing chromone moiety as mTOR/PI3Kα inhibitors.
    Zhu W; Chen C; Sun C; Xu S; Wu C; Lei F; Xia H; Tu Q; Zheng P
    Eur J Med Chem; 2015 Mar; 93():64-73. PubMed ID: 25659752
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 4-methylpteridinones as orally active and selective PI3K/mTOR dual inhibitors.
    Liu KK; Bagrodia S; Bailey S; Cheng H; Chen H; Gao L; Greasley S; Hoffman JE; Hu Q; Johnson TO; Knighton D; Liu Z; Marx MA; Nambu MD; Ninkovic S; Pascual B; Rafidi K; Rodgers CM; Smith GL; Sun S; Wang H; Yang A; Yuan J; Zou A
    Bioorg Med Chem Lett; 2010 Oct; 20(20):6096-9. PubMed ID: 20817449
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In Silico Analyses and Cytotoxicity Study of Asiaticoside and Asiatic Acid from Malaysian Plant as Potential mTOR Inhibitors.
    Zulkipli NN; Zakaria R; Long I; Abdullah SF; Muhammad EF; Wahab HA; Sasongko TH
    Molecules; 2020 Sep; 25(17):. PubMed ID: 32887218
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis of 5-substituted-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-one analogs and their biological evaluation as anticancer agents: mTOR inhibitors.
    Reddy GL; Guru SK; Srinivas M; Pathania AS; Mahajan P; Nargotra A; Bhushan S; Vishwakarma RA; Sawant SD
    Eur J Med Chem; 2014 Jun; 80():201-8. PubMed ID: 24780597
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of mammalian target of rapamycin (mTOR) kinase inhibitor CC-223.
    Mortensen DS; Perrin-Ninkovic SM; Shevlin G; Zhao J; Packard G; Bahmanyar S; Correa M; Elsner J; Harris R; Lee BG; Papa P; Parnes JS; Riggs JR; Sapienza J; Tehrani L; Whitefield B; Apuy J; Bisonette RR; Gamez JC; Hickman M; Khambatta G; Leisten J; Peng SX; Richardson SJ; Cathers BE; Canan SS; Moghaddam MF; Raymon HK; Worland P; Narla RK; Fultz KE; Sankar S
    J Med Chem; 2015 Jul; 58(13):5323-33. PubMed ID: 26083478
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovering novel P38α inhibitors for the treatment of prostate cancer through virtual screening methods.
    Li K; Li Z; Tao Y; Wang Q; Lai Y; Wu W; Peng S; Guo Z; Huang H
    Future Med Chem; 2019 Dec; 11(24):3125-3137. PubMed ID: 31838901
    [No Abstract]   [Full Text] [Related]  

  • 33. Discovery of novel hybrids of mTOR inhibitor and NO donor as potential anti-tumor therapeutics.
    Gao X; Zhao F; Wang Y; Ma X; Chai H; Han J; Fang F
    Bioorg Med Chem; 2023 Aug; 91():117402. PubMed ID: 37421709
    [TBL] [Abstract][Full Text] [Related]  

  • 34. mTOR inhibitors induce apoptosis in colon cancer cells via CHOP-dependent DR5 induction on 4E-BP1 dephosphorylation.
    He K; Zheng X; Li M; Zhang L; Yu J
    Oncogene; 2016 Jan; 35(2):148-57. PubMed ID: 25867072
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design, synthesis, in-vitro antiproliferative activity and kinase profile of new picolinamide based 2-amido and ureido quinoline derivatives.
    El-Damasy AK; Seo SH; Cho NC; Kang SB; Pae AN; Kim KS; Keum G
    Eur J Med Chem; 2015 Aug; 101():754-68. PubMed ID: 26218653
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of 5-(2-(phenylamino)pyrimidin-4-yl)thiazol-2(3H)-one derivatives as potent Mnk2 inhibitors: synthesis, SAR analysis and biological evaluation.
    Diab S; Teo T; Kumarasiri M; Li P; Yu M; Lam F; Basnet SK; Sykes MJ; Albrecht H; Milne R; Wang S
    ChemMedChem; 2014 May; 9(5):962-72. PubMed ID: 24677692
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Benzofuran derivatives as anticancer inhibitors of mTOR signaling.
    Salomé C; Ribeiro N; Chavagnan T; Thuaud F; Serova M; de Gramont A; Faivre S; Raymond E; Désaubry L
    Eur J Med Chem; 2014 Jun; 81():181-91. PubMed ID: 24836070
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PDK1 is a potential therapeutic target against angiosarcoma cells.
    Wada M; Horinaka M; Yasuda S; Masuzawa M; Sakai T; Katoh N
    J Dermatol Sci; 2015 Apr; 78(1):44-50. PubMed ID: 25726712
    [TBL] [Abstract][Full Text] [Related]  

  • 39. mTOR kinase inhibitors as a treatment strategy in hematological malignancies.
    Grzybowska-Izydorczyk O; Smolewski P
    Future Med Chem; 2012 Mar; 4(4):487-504. PubMed ID: 22416776
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimization of a Series of Triazole Containing Mammalian Target of Rapamycin (mTOR) Kinase Inhibitors and the Discovery of CC-115.
    Mortensen DS; Perrin-Ninkovic SM; Shevlin G; Elsner J; Zhao J; Whitefield B; Tehrani L; Sapienza J; Riggs JR; Parnes JS; Papa P; Packard G; Lee BG; Harris R; Correa M; Bahmanyar S; Richardson SJ; Peng SX; Leisten J; Khambatta G; Hickman M; Gamez JC; Bisonette RR; Apuy J; Cathers BE; Canan SS; Moghaddam MF; Raymon HK; Worland P; Narla RK; Fultz KE; Sankar S
    J Med Chem; 2015 Jul; 58(14):5599-608. PubMed ID: 26102506
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.